RenovoRx announces key leadership promotions
RNXT
-1.71%
Add to/Remove from Watchlist
Add to Watchlist
Add Position
Position added successfully to:
Please name your holdings portfolio
Type:
BUY
SELL
Date:
Amount:
Price
Point Value:
Leverage:
1:1
1:10
1:25
1:50
1:100
1:200
1:400
1:500
1:1000
Commission:
Create New Watchlist
Create
Create a new holdings portfolio
Add
Create
+ Add another position
Close
LOS ALTOS, Calif. – RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company specializing in precision oncology therapies, has announced the promotion of two senior members to its leadership team. Leesa Gentry has been elevated to Chief Clinical Officer, and Ronald B. Kocak, CPA, now serves as the Principal Accounting Officer.
The promotions, according to CEO Shaun Bagai, are a testament to the company’s commitment to advancing its clinical programs, particularly the TIGeR-PaC Phase III study for its lead product candidate, RenovoGemTM, which is aimed at treating Locally Advanced Pancreatic Cancer (LAPC). Bagai expressed gratitude for Gentry’s and Kocak’s contributions and dedication to the company.
Gentry, who joined RenovoRx in April 2023 as Senior Vice President of Clinical Operations, will now oversee clinical and regulatory operations. She played a pivotal role in the first interim analysis of the TIGeR-PaC study, which was recommended to continue by the Data Monitoring Committee. The study’s primary endpoint is to demonstrate a 6-month Overall Survival benefit, with secondary endpoints including reduced side effects compared to standard care.
Kocak, who has been with RenovoRx since October 2021, will continue in his roles as Vice President and Controller while taking on the new responsibilities as Principal Accounting Officer. His expertise in financial reporting and accounting was instrumental in completing a recent $6.1 million private placement, which extended the company’s cash runway.
RenovoRx’s Trans-Arterial Micro-Perfusion (TAMP) therapy platform, which the company is developing, aims to deliver precise therapeutic treatment directly to tumors, potentially minimizing toxicity compared to systemic therapies. RenovoGem, which is under investigation for TAMP delivery, has not yet been approved for commercial sale.
The company’s press release also contains forward-looking statements regarding the expected benefits of the executive promotions and the progress of their clinical trials and research. These statements are based on current expectations and involve risks and uncertainties that could cause actual results to differ materially.
This news is based on a press release statement from RenovoRx, Inc.
